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Introduction
The World Health Organization (WHO) estimates that, in 2014, 1.1% of tuberculosis (TB) patients had rifampicin resistant (RMP-R) disease without additional resistance to isoniazid (INH) i.e. not multidrug resistant (MDR) . 1 This equates to approximately 40,000 notified pulmonary TB patients with RMP-R strains. demonstrated that RMP-R was related to worse treatment outcomes. 5 Some of the included patients had MDR disease, however, and no formal meta-analysis comparing the efficacy of different regimens was undertaken.
Given the variability in treatment guidance, we aimed to undertake an up-to-date systematic review and meta-analysis of RCTs of treatment regimens for RMP monoresistant disease. Figure 1 and Online Appendix 1 document our literature search. Reference lists of included papers and review articles were also mined. RCTs of antimicrobial regimens for TB patients indexed by 21 st January 2015 were included, provided that either treatment outcome or relapses post-treatment could specifically be extracted for patients with RMP monoresistant disease. TB deaths were also extracted. Studies were not excluded by language. HRS screened all of (and H-AH 10% of) the retrieved records. Both reviewers independently undertook the final stage of full text screening and extraction into a standardised predesigned spreadsheet. Discrepancies were resolved by discussion; other authors were consulted when required. Both reviewers assessed study quality. 6 Studies were deemed to have a high risk of bias from selective reporting if the overall RCT was not of patients with drug resistant strains. The thresholds for the attrition criteria were-≥10% losses during follow up across all study participants (ignoring exclusions for not fulfilling inclusion criteria), or ≥10% absolute difference in losses between study arms. Where drug resistance was not the primary focus of a study, attrition was assessed for the entire study population.
Study population and methods
This review was registered on PROSPERO (CRD42014015025). As this was a systematic review ethical approval and informed consent were not required.
Results
Of 12,604 de-duplicated publications found, only three reported outcomes specifically for patients with RMP monoresistant disease and had more than one such patient in their trial (Table 1 , Figure 1 ). Consensus between the two reviewers on publications for inclusion was 100%. No study focussed solely on the treatment of patients with drug resistant strains or had more than five RMP-R patients for whom outcomes were reported. All studies recruited patients with pulmonary disease and utilised RMP in every treatment arm. None trialled the treatment regimens recommended by the WHO, NICE or ATS. The risk of bias for various quality domains was frequently unknown ( Table 1 ).
The Hong Kong Chest Service study contained two relevant patients for whom outcome data were extractable, one per regimen arm. only 49 patients few conclusions could be drawn. 10 Such studies are more subject to bias than RCTs, and frequently insufficient for the formulation of evidence-based guidance.
It is unclear if current WHO guidance results in over-treatment of non-MDR RMP-R disease;
indeed, it may be appropriate if weaker regimens are inadequate. Lengthy treatments with unpleasant adverse events can reduce patient adherence, increasing the likelihood of further drug resistance and onward transmission to others. Therefore, given the duration and toxicity of MDR-TB regimens, minimising unnecessary exposure of non-MDR RMP-R patients to such treatments, whilst ensuring an effective cure, is a priority.
Conclusions
To provide a solid scientific foundation for global treatment guidance, and given current data sparsity, we recommend that a properly powered RCT is undertaken to answer unresolved questions concerning the efficaciousness of different treatment regimens for RMP monoresistant disease. 
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